Dapagliflozin

Farxiga · Forxiga

Other GLP-1 Oral FDA/EMA Label

Half-life

12.9 hr

Time to Peak

2 hr

Steady State

~3 days

Bioavailability

78%

Dose Range

5–10 mg

Frequency

once daily

Overview

SGLT2 inhibitor similar to empagliflozin. FDA-approved for diabetes, heart failure, and chronic kidney disease. Often co-prescribed with GLP-1 agonists for complementary glucose-lowering.

Mechanism of Action

Selective SGLT2 inhibitor. Blocks renal glucose reabsorption in the proximal tubule, promoting urinary glucose excretion and reducing blood glucose.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Oral	5–10 mg	12.9 hr	2 hr	once daily

Used in Regimens

Dapagliflozin is not currently part of any catalog regimen.

Data Sources

FDA Label Farxiga (dapagliflozin) FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Dapagliflozin with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.